Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. (Q36070796)

12 August 2017

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. (English)

1 reference

12 August 2017

chronic myeloid leukemia

0 references

1 reference

Michael Lauseker

4

0 references

Stefan W. Krause

Stefan W Krause

27

0 references

Andreas Hochhaus

Andreas Hochhaus

31

0 references

Alice Fabarius

8

Alice Fabarius

1 reference

12 August 2017

Elisabeth Oppliger Leibundgut

25

Elisabeth Oppliger Leibundgut

1 reference

12 August 2017

32

Markus Pfirrmann

0 references

author name string

Susanne Saussele

1

1 reference

12 August 2017

Marie-Paloma Krauss

2

1 reference

12 August 2017

Rüdiger Hehlmann

3

1 reference

12 August 2017

Ulrike Proetel

5

1 reference

12 August 2017

Lida Kalmanti

6

1 reference

12 August 2017

Benjamin Hanfstein

7

1 reference

12 August 2017

Doris Kraemer

9

1 reference

12 August 2017

Wolfgang E Berdel

10

1 reference

12 August 2017

Martin Bentz

11

1 reference

12 August 2017

Peter Staib

12

1 reference

12 August 2017

Maike de Wit

13

1 reference

12 August 2017

Martin Wernli

14

1 reference

12 August 2017

Florian Zettl

15

1 reference

12 August 2017

Holger F Hebart

16

1 reference

12 August 2017

Markus Hahn

17

1 reference

12 August 2017

Jochen Heymanns

18

1 reference

12 August 2017

Ingo Schmidt-Wolf

19

1 reference

12 August 2017

Norbert Schmitz

20

1 reference

12 August 2017

Michael J Eckart

21

1 reference

12 August 2017

Winfried Gassmann

22

1 reference

12 August 2017

Andrea Bartholomäus

23

1 reference

12 August 2017

Antonio Pezzutto

24

1 reference

12 August 2017

Dominik Heim

26

1 reference

12 August 2017

Andreas Burchert

28

1 reference

12 August 2017

Wolf-Karsten Hofmann

29

1 reference

12 August 2017

Joerg Hasford

30

1 reference

12 August 2017

Markus Pfirrmann

32

1 reference

12 August 2017

Martin C Müller

33

1 reference

12 August 2017

Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group

34

1 reference

12 August 2017

language of work or name

English

0 references

publication date

27 April 2015

1 reference

12 August 2017

1 reference

12 August 2017

126

1 reference

12 August 2017

1

1 reference

12 August 2017

42-49

1 reference

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Comorbid diseases interact with breast cancer to affect mortality in the first year after diagnosis--a Danish nationwide matched cohort study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Standardized definitions of molecular response in chronic myeloid leukemia.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Tutorial in biostatistics: competing risks and multi-state models

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Validation of a combined comorbidity index

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4574015

Evaluation of patients with advanced cancer using the Karnofsky performance status

5 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25918346

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2015-01-617993

1 reference

12 August 2017

1 reference

12 August 2017

1 reference